Paradromics | Competitive Intelligence Insights - Apr 28, 2025
Stephen Ryu has joined Paradromics as Chief Medical Officer in the United States, previously serving in the same role at another company...
Brought to you by RivalSense - an AI tool for monitoring any company.
RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡
Paradromics
🌎 paradromics.comParadromics is a biotechnology research company focused on developing advanced brain-computer interface (BCI) technologies aimed at improving brain health. Founded in 2015, the company specializes in high-resolution neural interfaces that decode brain activity to provide solutions for various medical conditions, including paralysis, chronic pain, and mental health disorders. Their flagship product, Connexus, is designed for long-term medical use and aims to help individuals with unmet medical needs.
Paradromics - Latest News and Updates
- Stephen Ryu has joined Paradromics as Chief Medical Officer in the United States, previously serving in the same role at another company.
- Leo Lion Limited has invested in Paradromics to support their development of high-bandwidth brain-computer interfaces aimed at restoring communication for people with severe neurological conditions.
- Paradromics announced Stephen Ryu, MD, as Chief Medical Officer.
- On May 14, 2025, Prof Andreas Schaefer, Co-Founder of Paradromics, will participate in a panel discussion at Jesus College, Oxford, about the science and ethics of brain-computer interfaces.
- Matt Angle, CEO of Paradromics, discussed using brain implants to restore senses for the blind or deaf by directly inputting data from cameras or microphones.
Sign up to receive regular updates
If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.
